Last reviewed · How we verify
valsartan/atenolol
This combination drug lowers blood pressure by blocking angiotensin II receptors (valsartan) and beta-adrenergic receptors (atenolol) to reduce vasoconstriction and heart rate.
This combination drug lowers blood pressure by blocking angiotensin II receptors (valsartan) and beta-adrenergic receptors (atenolol) to reduce vasoconstriction and heart rate. Used for Hypertension.
At a glance
| Generic name | valsartan/atenolol |
|---|---|
| Sponsor | Novartis |
| Drug class | Angiotensin II receptor blocker / Beta-blocker combination |
| Target | AT1 receptor (angiotensin II type 1) / Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Atenolol is a beta-1 selective adrenergic antagonist that decreases heart rate and cardiac contractility. Together, these complementary mechanisms provide synergistic blood pressure reduction.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Bradycardia
- Cough
Key clinical trials
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial) (PHASE4)
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment (PHASE4)
- Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients. (PHASE4)
- VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women (PHASE4)
- Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol (PHASE4)
- Black Education and Treatment of Hypertension (BEAT HTN) (PHASE4)
- Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- valsartan/atenolol CI brief — competitive landscape report
- valsartan/atenolol updates RSS · CI watch RSS
- Novartis portfolio CI